Scott Giberson - 13 Sep 2022 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Director
Signature
/s/ Scott Giberson
Issuer symbol
SABS
Transactions as of
13 Sep 2022
Net transactions value
$0
Form type
4
Filing time
15 Sep 2022, 17:00:13 UTC
Previous filing
13 Jul 2022
Next filing
17 Jul 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award $0 +25,000 $0.000000 25,000 13 Sep 2022 Common Stock 25,000 $0.7100 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.
F2 The shares underlying the option vest over a three-year period, vesting 1/36 monthly beginning with the month following the Reporting Person's commencement of service as a director (July 6, 2022). This represents the initial grant to the Reporting Person as a member of the Board of Directors.